Lactate and Alanine Cycles

Cancer metabolism / carbon, nitrogen and interorgan exchange

How Cancer Rewires the Lactate and Alanine Cycles

The familiar muscle–liver loops become part of a wider network: tumors can release fuels, consume them, and change the signals that govern metabolism elsewhere in the body.

A diagram of the Cori and glucose–alanine cycles usually shows muscle on one side and liver on the other. Muscle exports lactate or alanine; the liver uses their carbon to make glucose, which returns to the circulation. In the alanine cycle, nitrogen travels with the carbon.

Cancer adds participants and changes the traffic. A tumor may contribute lactate to the circulation, consume lactate produced elsewhere, take up alanine from neighboring cells, or send signals that alter liver glucose production. Understanding this rewiring means asking where the carbon came from, where the nitrogen goes, and which tissue pays the energy cost.

Cancer-associated metabolic rewiring can change the rate, destination and regulation of normal pathways. The pattern depends on the tumor, its environment, the host and the stage of disease.

Explore the seven routes

Lactate carbon returns as glucose

Normal physiology
Glucose Lactate Alanine · carbon + amino N
Seven views of the network. Parts 1–2 establish normal physiology; parts 3–7 add cancer-associated routes and signals. The animation combines findings from different studies into an illustrative network, not a single experimentally demonstrated sequence in every patient. Particle speed and number do not represent measured metabolic rates.

Recycling carbon—and transporting nitrogen

The Cori cycle

Glucose is converted into pyruvate and then lactate. Lactate reaches the liver, where its carbon can return to glucose through gluconeogenesis. This conserves carbon and shifts part of the metabolic workload between tissues.[1]

The glucose–alanine cycle

Muscle transfers amino groups from glutamate to pyruvate, producing alanine. The liver reverses this transamination: alanine supplies pyruvate for glucose synthesis, while its nitrogen can enter urea synthesis.[2]

Alanine aminotransferase, abbreviated ALT, connects these carbon and nitrogen routes:

Pyruvate + glutamateAlanine + α-ketoglutarate

Alanine therefore carries bound amino nitrogen, rather than a parcel of free ammonia. Its three-carbon skeleton can originate from glucose-derived pyruvate. Increased alanine production does not, by itself, establish that all of its carbon came from the breakdown of muscle protein.

The two-organ picture is also a simplification. Lactate moves among multiple tissues and can be oxidized directly. Mouse isotope-tracing studies demonstrate extensive use of circulating lactate as a carbon source, with contributions that depend on tissue and metabolic state. A lactate molecule does not have to complete a trip through the liver before it becomes useful again.[3]

The cost of completing a Cori loop

Converting one glucose into two lactates yields 2 ATP. Rebuilding glucose from those lactates consumes 4 ATP + 2 GTP, equivalent to six high-energy phosphate bonds. The complete loop therefore has a net cost of 4 ATP equivalents per glucose recycled.[1]

This is the stoichiometric cost of that defined loop. It is not a measured energy deficit for a patient, and it is not the full energy accounting for the alanine cycle, which also handles nitrogen.

The tumor can export the recycling workload

Many tumors convert a substantial share of glucose into lactate, including when oxygen is available—the phenomenon called aerobic glycolysis or the Warburg effect. The exported lactate can join the circulating pool and become a substrate for liver glucose production. This adds a tumor–liver route alongside the familiar muscle–liver route.[4] [1]

Liver glucose→Tumor glycolysis→Lactate→Liver glucose synthesis

There is human evidence for increased recycling in particular settings. Holroyde and colleagues studied 12 weight-losing patients with metastatic colorectal cancer and found increased glucose production and recycling through lactate compared with controls.[5]

But this finding is not universal. Lundholm and colleagues reported increased glucose turnover without an increase in net glucose-carbon recycling in a different cancer cohort. The studies used different populations and methods; together, they argue against assigning one metabolic pattern to all cancers.[6]

The potential burden depends on how much carbon actually completes the loop. Some lactate is oxidized elsewhere, some carbon enters biosynthesis, and the circulation mixes inputs from many tissues. High tumor lactate production alone cannot quantify the whole-body cost of Cori recycling.

A connection to cachexia, with limits on what it proves

In cancer-associated wasting, altered muscle amino-acid metabolism can supply substrates for continued glucose production. The alanine cycle provides a route linking amino-group transfer in peripheral tissue to glucose synthesis and nitrogen disposal in the liver. It does not, on its own, explain the full syndrome of muscle loss.

A human tracer study compared 9 weight-losing lung cancer patients, 10 weight-stable patients and 15 healthy controls. Alanine turnover and glucose production from alanine were higher in the weight-losing group. These changes were associated with the degree of weight loss rather than simply the presence of lung cancer.[7]

That is evidence of altered metabolic traffic. It does not demonstrate that every alanine molecule originated in muscle, that every resulting glucose molecule fed the tumor, or that accelerating this cycle was the sole cause of wasting. Glucose released by the liver enters a shared circulation and remains available to normal tissues as well.

Concentration is not traffic

In the same study, plasma alanine concentrations did not differ significantly between groups despite the differences in turnover. A blood concentration describes the size of a circulating pool; isotope tracing helps reveal how quickly material enters, leaves and changes form.[7]

Lactate and alanine can feed tumors directly

The textbook arrows point toward the liver. Cancer metabolism adds routes into tumor cells, without requiring an intermediate conversion into circulating glucose.

Human tumor tracing

Lactate as a mitochondrial fuel

Faubert and colleagues infused labeled lactate into patients with non-small-cell lung cancer and detected its carbon in tumor TCA-cycle metabolites. This supports lactate use in living human tumors. In accompanying mouse experiments, deletion of the transporter MCT1 prevented lactate-dependent labeling, helping establish the uptake mechanism.[4]

A tumor can combine glycolysis with mitochondrial metabolism. Lactate production and lactate use can coexist across cells or regions.

Preclinical pancreatic cancer models

Alanine from the surrounding stroma

Sousa and colleagues showed that pancreatic stellate cells release alanine through an autophagy-dependent process stimulated by cancer cells. Pancreatic cancer cells use this alanine carbon to support the TCA cycle and biosynthesis, including lipid synthesis.[8]

This is a local exchange between stromal and cancer cells. It is distinct from muscle–liver cycling and does not establish the same dependency in every human tumor.

The fate of a metabolite depends on the cell receiving it. Hepatic alanine metabolism can support glucose synthesis and nitrogen disposal; tumor alanine metabolism may supply carbon for oxidation and construction of new cellular material. The same name on a blood test can therefore conceal several different biological destinations.

The liver can receive new metabolic instructions

A tumor can influence liver metabolism through signaling as well as substrate delivery. A 2025 study using fly and mouse models identified tumor-associated signaling through IL-6/JAK–STAT in mammals and a related pathway in flies. The work linked these signals to hepatic gluconeogenic programs and increased expression of PDK3.[9]

PDK3 inhibits pyruvate dehydrogenase, which controls pyruvate entry into acetyl-CoA formation. Restricting this oxidative route, together with activation of glucose-producing pathways, can favor the use of available substrates for gluconeogenesis.

The causal evidence comes mainly from experimental models. Human associations add relevance, but do not establish that this pathway drives every case of cancer cachexia or that targeting it improves patient outcomes. In the animation, the dashed arrow marks a regulatory signal, not a transfer of lactate, alanine or their carbon.

Which part of the rewiring has actually been measured?

Different experiments answer different questions.
Route or changeEvidenceWhat remains conditional
More glucose recycling through lactateMeasured in some human cancer cohorts.[5] [6]Its presence and magnitude vary; it is not a universal explanation for wasting.
Greater alanine-to-glucose fluxHuman lung cancer tracer study associated with weight loss.[7]Association does not identify every tissue source or prove the cause of muscle loss.
Lactate used by tumor mitochondriaHuman lung tumor tracing, with mechanistic mouse experiments.[4]Fuel contributions differ across tumors and conditions.
Stromal alanine supports cancer metabolismPancreatic cancer cell and animal models.[8]Local exchange is not proof of a universal human dependency.
Signals alter hepatic glucose productionCausal work in experimental models; accompanying human associations.[9]Clinical benefit from targeting the pathway remains a separate question.

The animation brings these findings together for explanation. It does not assign a measured flow rate to any arrow or establish that every route is active simultaneously in an individual tumor.

A useful investigation must distinguish pool size, exchange and net flux. Increased glucose uptake does not specify whether its carbon becomes lactate, enters mitochondria or supplies biosynthesis. Increased alanine turnover does not directly measure net muscle protein loss. Whole-body measurements and measurements inside a tumor answer related but different questions.

The rewiring extends beyond the cancer cell. It changes how tissues share carbon, transport nitrogen and allocate the cost of maintaining glucose supply. Understanding those exchanges reveals both the tumor’s metabolic flexibility and the demands placed on its host.

References

Primary studies supporting the pathways and evidence distinctions described above.

  1. Visavadiya NP, Rossiter HB, Khamoui AV (2021). Distinct glycolytic pathway regulation in liver, tumour and skeletal muscle of mice with cancer cachexia. Cell Biochemistry and Function. 39:802–812.Mouse study; biochemical context for Cori cycling and tissue-specific regulation. ↩ Back to text
  2. Felig P, Pozefsky T, Marliss E, Cahill GF Jr (1970). Alanine: key role in gluconeogenesis. Science. 167:1003–1004.Human physiological measurements of muscle alanine release and hepatic handling. ↩ Back to text
  3. Hui S et al. (2017). Glucose feeds the TCA cycle via circulating lactate. Nature. 551:115–118.Mouse isotope tracing and flux modeling; tissue and feeding-state dependence. ↩ Back to text
  4. Faubert B et al. (2017). Lactate Metabolism in Human Lung Tumors. Cell. 171:358–371.e9.Human lung tumor isotope tracing with complementary mechanistic mouse experiments. ↩ Back to text
  5. Holroyde CP, Skutches CL, Boden G, Reichard GA (1984). Glucose metabolism in cachectic patients with colorectal cancer. Cancer Research. 44:5910–5913.Human metabolic tracer study in 12 weight-losing patients with metastatic colorectal cancer. ↩ Back to text
  6. Lundholm K, Edström S, Karlberg I, Ekman L, Scherstén T (1982). Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. Cancer. 50:1142–1150.Human tracer study; elevated turnover did not entail increased net glucose-carbon recycling. ↩ Back to text
  7. Leij-Halfwerk S et al. (2000). Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. American Journal of Clinical Nutrition. 71:583–589.Cross-sectional human tracer study; weight-losing and weight-stable cancer groups and healthy controls. ↩ Back to text
  8. Sousa CM et al. (2016). Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 536:479–483.Preclinical stromal–tumor metabolic interaction; the online article incorporates the figure-label erratum. ↩ Back to text
  9. Liu Y et al. (2025). Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice. Nature Metabolism. 7:823–841.Causal experiments in fly and mouse models, with accompanying human associative analyses. ↩ Back to text

No comments:

Post a Comment